Stories

Ipsen is not new to aesthetics. For more than three decades, we have been advancing neuroscience innovations across therapeutic and aesthetic indications, building deep expertise in complex biologics, rigorous clinical development and high‑quality manufacturing.

Ipsen reports 22.6% sales growth at constant exchange rates in Q1 2026, reflecting balanced growth across Oncology, Rare Disease, and Neuroscience.

For the hundreds of children diagnosed with pediatric low-grade glioma (pLGG) across Europe each year, the journey is rarely what families expect. It is often long, complex, and life-altering. However today, we’re excited that the treatment landscape has progressed.  

In the pharmaceutical industry, it’s easy to focus on data, strategy, and performance metrics. But behind every decision are real people. For Guillermo Castillo Acero, Head of European Mid-Sized Markets at Ipsen, that reality became clear during a precise moment in his career.

For too long, modern medicine has treated diseases as if they were uniform, defined by a label rather than by their underlying biology. Today, we have an unprecedented ability to interrogate the molecular drivers that shape each person’s cancer, and in doing so, we’re transforming how we diagnose, develop and deliver the medicines that matter most.